Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
Charles T. Robbins(Yale University), David L. Rimm(Yale University), Kamaljeet Singh, T. Rinda Soong(University of Pittsburgh Medical Center), Julie M. Jorns(Medical College of Wisconsin), Krisztina Hanley(Emory University), Emily Reisenbichler(Saint Louis University), Oluwole Fadare(University of California, San Diego), Olivia L. Snir(Oregon Health & Science University), Aileen I. Fernandez(Yale University), Malini Harigopal, Gang Han(Texas A&M Health Science Center), Mirna Podoll(Breast Cancer Research Foundation), Hannah Y. Wen(Memorial Sloan Kettering Cancer Center), Mary Ann Sanders(University of Louisville), Kim Rabe(University of Minnesota), Wei Shi(Chinese Academy of Sciences), Amy Ly(Washington University in St. Louis), Serena Wong(Yale University), M. Gabriela Kuba(Memorial Sloan Kettering Cancer Center), Jane Brock(Brigham and Women's Hospital), Esther Yoon(Cleveland Clinic Florida)
Cited by 98
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753